ABSTRACT
Prevention of infectious diseases in cancer patients is an important clinical problem, since the approach to cancer treatment of neoplastic diseases has been intensified significantly during recent decades. Cancer patients are frequently predisposed to infections because of their immunosuppression. The disease itself or/and its treatment precipitates this immunological decline: leukemia, lymphoma, generalized malignancy, or treatment with chemotherapy, radiation, or prolonged high-dose corticosteroids. There is a preponderance of infectious agents that can infect immunocompromised cancer patients for which no vaccine is available [1,2] (Table I). In these situations, the use of antibiotics remains the main focus in clinical practice [3].
